News

The Phase III program will include more than 4,000 patients. The Phase III program for albiglutide will begin with five studies in early 2009. The objective of the

In the transaction, GPC Biotech is to be merged onto a new German company, which will hold all of the shares of Agennix and a E15 million cash

Syncria is the fifth product to which Human Genome Sciences (HGS) has substantial financial rights that has entered late-stage clinical development. Syncria was created by HGS using its

Dermagraft, which is manufactured and marketed by Advanced BioHealing (ABH), is a human derived dermal substitute approved by the FDA for the treatment of diabetic foot ulcers (DFU).

The SonaStar is used by Neuro and General Surgeons for quick and efficient removal of both hard and soft tumors while sparing most vessels. Apart from this, OsteoSculpt

The vaccine, which does not contain an adjuvant, induced robust hemagglutination inhibition (HAI) responses, which have been shown to be important for protection against influenza disease. Novavax’s virus-like

The company expects to use the proceeds from the financing to complete the submission of a new drug application to the FDA for its lead product candidate, Davanat,

In the Phase II study in treatment-naive patients infected with hepatitis C virus (HCV) genotype 4, 82% (n=17) and 100% (n=16) of patients receiving low and high doses

Synta has earned a total of $130 million in payments from GlaxoSmithKline (GSK) to date, including the $80 million upfront payment in 2007, $40 million for milestones achieved